Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBIT Margin (2019 - 2025)

Pulmonx (LUNG) has disclosed EBIT Margin for 7 consecutive years, with 66.94% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 237.0% to 66.94% in Q3 2025 year-over-year; TTM through Sep 2025 was 62.38%, a 1102.0% increase, with the full-year FY2024 number at 68.87%, up 2132.0% from a year prior.
  • EBIT Margin was 66.94% for Q3 2025 at Pulmonx, down from 62.05% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 56.46% in Q4 2024 to a low of 145.28% in Q1 2022.
  • A 5-year average of 88.57% and a median of 85.9% in 2023 define the central range for EBIT Margin.
  • Biggest YoY gain for EBIT Margin was 21467bps in 2021; the steepest drop was -6433bps in 2021.
  • Pulmonx's EBIT Margin stood at 90.21% in 2021, then dropped by -5bps to 94.83% in 2022, then increased by 24bps to 72.2% in 2023, then grew by 22bps to 56.46% in 2024, then fell by -19bps to 66.94% in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBIT Margin are 66.94% (Q3 2025), 62.05% (Q2 2025), and 64.62% (Q1 2025).